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Protein glycosylation is one of the most common posttranslational modiﬁcations in mammalian cells. It is involved in many
biological pathways and molecular functions and is well suited for proteomics-based disease investigations. Aberrant protein
glycosylation may be associated with disease processes. Speciﬁc glycoforms of glycoproteins may serve as potential biomarkers
for the early detection of disease or as biomarkers for the evaluation of therapeutic eﬃcacy for treatment of cancer, diabetes, and
otherdiseases.Recenttechnologicaldevelopments,includinglectinaﬃnitychromatographyandmassspectrometry,haveprovided
researchers the ability to obtain detailed information concerning protein glycosylation. These in-depth investigations, including
proﬁling and quantifying glycoprotein expression, as well as comprehensive glycan structural analyses may provide important
information leading to the development of disease-related biomarkers. This paper describes methodologies for the detection of
cancer-related glycoprotein and glycan structural alterations and brieﬂy summarizes several current cancer-related ﬁndings.
1.Introduction
Within the past decade, proteomics has become an intensive
ﬁeld of research; one which may help to deﬁne biomarkers
that could facilitate the early detection of disease or to pro-
vide important information for risk stratiﬁcation, prediction
of therapeutic eﬃcacy, and disease prognosis. Proteins are
known to be involved in biological activity and physiological
changes in organisms [1]. Large-scale proﬁling of cellular
proteins, using comparative expression levels between dis-
ease and normal homeostatic conditions, may reveal the ba-
sic underpinnings of disease processes. It may also facilitate
the identiﬁcation of proteins that are modiﬁed, either in
structure or in levels of expression. Along with proteomic
analysis of proteins, the analysis of protein posttranslational
modiﬁcations (PTMs) also plays an important role in the
study of disease. There are many types of PTMs, including
acetylation, ubiquitination, phosphorylation, and glycosyla-
tion [2]. Each type of PTM may play a signiﬁcant role in
protein functionality. It is estimated that PTMs can be found
on up to 80% of mammalian proteins [3]. Glycosylation is
one of the most common PTMs, estimated to be found on
over 50% of human proteins [4, 5].
Carbohydrate modiﬁcations are important in host-path-
ogen interactions, inﬂammation, development, and malig-
nancy. Aberrant glycosylation may result in abnormal
changes in biological function/activity, protein folding, and
molecular recognition in disease. As such, analysis of altered
cancer-related glycoprotein expression may facilitate dis-
covery of potential biomarkers, as well as discovery of
novel targets of therapeutics. Glycoproteins from various
biological samples that are known to be cancer biomarkers
are shown in Table 1. There are several diﬀerent types of
protein glycosylation, including (1) N-linked glycosylation,
(2) O-linked glycosylation, (3) C-glycosylation [6], and (4)
S-linked glycosylation (only found in bacteria) [7, 8]. N-gly-
cosylation occurs on the asparagine in the sequence of Asn-
X-Ser/Thr (and occasionally Cys) with X being any amino
acid with the exception of proline. It is initiated on the
cytoplasmic side of the rough endoplasmic reticulum (ER),
where the oligosaccharide Man5GlcNAc2 is delivered to the
precursor, dolichol pyrophosphate. The best known core
glycan precursor is Glc3Man9GlcNAc2-PP-dol [9–11]. N-
glycans can be further categorized by the type and position
of monosaccharide residues added to the core, being either2 International Journal of Proteomics
Table 1: List of some of the US Food and Drug Administration (FDA) approved glycoprotein cancer biomarkers. CA: cancer antigen, FDP:
ﬁbrin degradation protein, sPIgR: secreted chain of the polymeric immunoglobulin receptor.
Biomarker(a) Glycosylation Source Disease
CA15.3 Yes Serum Breast
CA27-29 Yes Serum Breast cancer
HER2/NEU Yes Serum Breast cancer
Fibrin/FDP Yes Urine Bladder
CEA (carcinoembryonic antigen) Yes Serum Colon cancer
Carcinoembryonic antigen (CEA) Yes Serum Colon, breast, lung, pancreatic
Epidermal growth factor receptor Yes Tissue Colon cancer
CA19-9 Yes Serum Gastrointestinal
KIT Yes Tissue Gastrointestinal tumor
α-fetoprotein(AFP) Yes Serum Hepatoma, testicular cancer
Human chorionic gonadotropin-β Yes Serum Testicular cancer
Thyroglobulin Yes Serum Thyroid cancer
CA125 Yes Serum Ovarian
PSA (prostate-speciﬁc antigen) Yes Serum Prostate
a high-mannose type, an antennary complex type, or a
hybrid type (Figure 1(a)[10]).Thehigh-mannosetypeofN-
glycan consists of mostly mannose in the core structure. The
complex type of N-glycan contains N-acetylgalactosamine
(Galβ1-3/4GlcNAc) in the N-glycan antennal region. The
antennae can be further extended by adding Gal and
GlcNAc residues. The hybrid type of N-glycan has both high
mannose and N-acetylglucosamine. High-mannose and hy-
brid types share some similar features, such as two-mannose
attachment on the trimannosyl core.
SerineorthreonineresiduescanbeO-glycosylatedbyad-
dition of N-acetylglucosamine, mannose, fucose, glucose, N-
acetylgalactosamine, or xylose (Figure 1(b)) [10, 11]. The
most common O-linked glycosylation is initiated by N-acet-
ylgalactosamine, bound through α-glycosidic linkages to
Ser/Thr residues. In mucin-type O-glycosylation (mucins
may be a cancer biomarker due to involvement in cancer de-
velopment and inﬂuence in cell adhesion, invasion, and
immune response [12]), the carbohydrate is linked to a
hydroxyl group on Ser/Thr residues. This linkage often oc-
curs while the protein is transiting through the Golgi appa-
ratus as it is being secreted through the classical secretory
pathway. The O-glycan core structure is formed by adding
galactose/N-acetylglucosamine and may also contain sialic
acid and/or fucose. C-glycosylation involves α-mannose C-
linked to tryptophan. Still yet, many glycans have further
modiﬁcations, such as sulfation and phosphorylation. The
degree of complexity of glycan structures/composition chan-
ges, and unknown modiﬁcation of glycans are beyond what
c a nb ea d e q u a t e l yd e s c r i b e di nt h i sp a p e r .H o w e v e r ,i ti si m -
portanttonotethatthiscomplexitydoescontributetocancer
glycoproteomics.
2.Glycoproteomics Methodology
In general, glycoproteomics methodology consists of glyco-
protein isolation, enrichment of the glycoproteins/glyco-
peptides, proteolytic digestion, and detection/identiﬁcation
of peptides or glycan structures using mass spectrometry-
based techniques. Since many biological samples, such as
plasma or serum, are very complex mixtures of proteins, ex-
tensive chromatographic separation techniques have been
utilized (including ionexchange,sizeexclusion,hydrophobic
interaction, and aﬃnity chromatography) in order to reduce
sample complexity and enhance dynamic ranges [13, 14].
Although glycoproteins can be separated by 2D-PAGE, their
hydrophobic nature and tendency to precipitate at their isoe-
lectric point, inadequate resolution, and the limited dynamic
range of the gel system tend to greatly limit recovery and
sequence coverage rates (by mass spectrometry). Following
separation, the glycoproteins can be identiﬁed by MALDI-
TOF-MS or LC-MS/MS. Recent technological improvements
with LC-MS/MS have allowed mass spectrometry to play a
major role in glycoproteomics analysis of disease. For glyco-
protein analysis, the most commonly used methodology is
a bottom-up approach [15] in which proteins are digested,
after which the peptides go through an enrichment process
or a deglycosylation process using Peptide N-Glycosidase F
(PNGase F). PNGase F cleaves between the innermost Glc-
NAc and asparagine residues from N-linked glycoproteins/
peptides, with the exception of ones carrying α1→3 linked
core fucose [16]. Following digestion, the peptides are sub-
jected to MS analysis. With MS data, bioinformatics with
various algorithms and glycol-related database are heavily
relied upon to analyze glycoproteins and glycans [17, 18].
UniProt and PeptideAtlas libraries [19] also can provide
information of glycoproteins and glycopeptide mass spectra.
Using this methodology, it is necessary to integrate obtained
data about the glycan and the glycoprotein [20]. Ultimately,
however,itischallengingtoﬁnddisease-relatedglycosylation
changes due to the relatively low abundance of the altered
glycan/glycoprotein structures.International Journal of Proteomics 3
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Figure 1: Common N- and O-linked glycans [10]. (a) Asparagine (N)-linked glycans, (b) serine/threonine (O)-linked glycans.
3. GlycoproteinEnrichmentby
LectinAfﬁnityChromatography
Lectin aﬃnity chromatographic enrichment is a routinely
utilized methodology designed to concentrate glycoproteins/
peptides that contain speciﬁc glycan structures, while elimi-
nating nonspeciﬁc binding [21–24]. Various lectins (Table 2)
can be used to isolate glycoproteins selectively based on gly-
can structure. As Concanavalin A (ConA) recognizes α-
linked mannose residues, it will bind to high mannosyl, gly-
cosyl, and hybrid-type glycans [25–27]. Wheat germ agglu-
tinin (WGA) will bind to N-acetylglucosamine and possibly
sialic acid residues on glycoproteins [28]. Aleuria aurantia
lectin (AAL) recognizes speciﬁc binding to L-fucose-contain-
ing oligosaccharides [29]. Jacalin lectin (JAC) preferentially
binds to galactosyl (β-1,3) N-acetylgalactosamine but will
also bind to other O-glycosidically linked oligosaccharides
(O-glycan) [30, 31]. In addition, there are many other lec-
tins, each with their own carbohydrate binding speciﬁcity.
Multiple agarose bound lectins can be used simultaneously/
sequentially to purify/enrich diﬀerent types of glycoproteins
from various complex protein mixtures [32–34]. Utilizing
multiple lectins provides the advantage of increasing detec-
tion coverage and providing global analysis. To date, how-
ever, lectin aﬃnity chromatography has been more focused
on the study of N-linked glycosylation, in part due to the fact
that lectin aﬃnity chromatography targets speciﬁc oligosac-
charide structures and isolation/puriﬁcation of O-linked
glycan structures still in need of technological improvement.
For the enrichment of O-linked glycosylation glycopro-
tein/glycopeptides, it is more common to use β-elimination
followed by Michael addition of DTT (BEMAD) or biotin-
pentylamine, to label the O-glycosylation site (O-GlcNAc)
[35]. Another method to isolate O-linked glycopeptides
utilizes hydrophilic binding followed by multiple-staged MS/
MS analysis [36, 37]. The detection of O-GlcNAc is challeng-
ing, since GlcNAcylation and phosphorylation are conﬁned
to a similar residue. One can also utilize galactosyltransferase
to tag O-GlcNAc with ketone biotin [38]. Another extraction
method,boronicacid-basedbeads,canprovidefast,eﬃcient,
and speciﬁc enrichment of glycoproteins by binding to cis-
diol groups on sugar residues [39, 40]. Hydrazide chemistry,4 International Journal of Proteomics
Table 2: A partial list of lectins commonly used for enrichment of glycoproteins/glycopeptides.
Lectin Speciﬁcity
Aleuria Aurantia Lectin (AAL) Fucα1-6 GlcNAc, Fucα1-3(Galβ1-4)GlcNAc
Concanavalin A (Con A) High-Mannose, Manα1-6(Manα1-3)Man
Erythrina Cristagalli Lectin (ECA) Galβ1-4GlcNAc
Hippeastrum Hybrid Lectin (HHL, AL) High-Mannose, Manα1-3Man, Manα1-6Man
Jacalin Galβ1-3GalNAc, GalNAc
Lens Culinaris Agglutinin (LCA) Fucα1-6 GlcNAc, α-D-Glc, α-D-Man
Maackia Amurensis Lectin (MAL) Siaα2-3Galβ1-4GlcNAc
Peanut Agglutinin (PNA) Galβ1-3GalNAc
Phaseolus vulgaris Leucoagglutinin (PHA-L) Tri/tetra-antennary complex-type N-glycan
Sambucus Nigra Lectin (SNA, EBL) Siaα2-6Gal/GalNAc
Ulex Europaeus Agglutinin-I (UEA-I) Fucα1-2Galβ1-4GlcNAc
Wheat Germ Agglutinin (WGA) Chitin oligomers, Sia
interacting with glycoprotein carbonyl groups [41, 42], has
a l s op r o v e dt ob eu s e f u la n di so f t e nc o m b i n e dwi t hl e c t i na f -
ﬁnity chromatography. Following the enrichment process,
further puriﬁcation with ethanol [43]o ra c e t o n e[ 44]a n da
C18 stationary phase [45] or graphitized carbon column
[46, 47] for glycans could be introduced prior to mass spec-
trometric analysis. For glycan analysis, lyophilization [48]o r
drying under nitrogen [49] is also useful, as increasing the
temperature of the sample could cause destruction of the
glycan. Further, solvent removal is very critical due to the
low quantity of glycan for detection. In order to increase ef-
ﬁciency of isolation and detection of glycoproteins from
complex protein lysates, the work ﬂow of an online lectin
microcolumn (ConA and SNA lectins) connected to LC-MS
hasbeenintroduced[50].Usingsilica-basedcolumnsinstead
ofagarose-basedcolumns,onlineselectiveconcentrationand
detection of glycoproteins/glycopeptides gave shorter analy-
sis time, reduced sample loss, and provided greater coverage
uniformity.
4. Mass Spectrometry for Glycopeptides
The most widely used methods for glycomics involve char-
acterization of glycopeptides generated by digestion and/or
deglycosylation. Directly analyzing glycoproteins with at-
tached glycans is complicated due to many fragment ions
from backbone peptides, carbohydrates, and also ions from
the mass spectrometry ion source. For mass analysis, there
are several instruments including MALDI-TOF/TOF (time-
of-ﬂight)-MS [51–53], electrospray-based quadrupole ion
trap (QIT) [54], quadrupole/TOF [55], Fourier transform
ion cyclotron resonance (FTICR) [56], Orbitrap [48, 57]
with CID (collision-induced dissociation), electron-capture
dissociation (ECD) [58, 59], electron-transfer disassociation
(ETD) [60, 61], and infrared multiphoton dissociation
(IRMPD) [62, 63]. MALDI ionization generates stable singly
charged precursor ions from the glycan. These precursor
ions can be later characterized, using the MS/MS mode, by
cleavage of glycosidic bonds and peptide with loss of glycan,
leaving information regarding the glycan moiety. TOF/TOF
fragmentation spectra could give additional attachment site
information [64, 65] and structural analysis [66, 67]. QTOF
mass spectrometers provide spectra with less chemical noise
than spectra obtained by triple quadrupole or MALDI mass
spectrometers. The advantages of using QTOF are higher
mass accuracy, sensitivity, and resolution, thereby being able
to detect ions with low intensity. Also, QTOF mass spec-
trometry could determine sensitive glycosylation site(s) and
of the type of attached carbohydrate moiety [68]. FT-ICR-
MS with ECD or IRMPD is very powerful tool for study of
glycomics, since not only does FT-ICR-MS have high mass
accuracy and high mass resolution, but also it has the ability
to sequence peptides with no loss of glycans when it is
equipped with ECD. It can also produce abundant fragment
ions with IRMPD, resulting from dissociation at glycosidic
linkages [57, 64].
5. Mass Spectrometry for Glycans
N-glycan release, resulting from cleavage with PNGase F, and
O-glycan release by chemical methods [69]c a nb ed e t e c t e d
by mass spectrometry, although it is often necessary to adapt
another step to improve ionization of the glycans, such as
by permethylation [70, 71] or methylation [72, 73]d e r -
ivatization [74, 75]. Figure 2 shows the nomenclature for
tandem mass spectrometric product ions of glycans and gly-
coconjugated forms [76]. Neutral glycan produces gave
singly and doubly charged ions and strong signals with
[M+Na]+, often along with [M+K]+ ions. Also, cross-ring
and c-type fragmentation could be generated with CID. In
ordertoincreasetheglycansignal,stableanionicadductscan
be generated by having unstable adducts react with chloride,
bromide, iodide, nitrate, and phosphate, with the products
analyzed in negative mode. Occasionally, glycan analysis in
negative mode provides great advantage for a strong signal,
and yet still contains structural information. Acidic glycan
gives ions in higher charge states due to anionic groups. It
will also fragment diﬀerently due to charge localization [77].
Glycans with diﬀerent isoforms from glycoconjugates can be
also detected with ion mobility, since ion mobility can diﬀerInternational Journal of Proteomics 5
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Figure 2: Nomenclature for tandem mass spectrometric product
ionsofglycansandglycoconjugatedforms.Ionsretainingthecharge
at the reducing terminus are named X, Y, and Z. Complementary
ions are labeled A, B, and C [76].
based on molecular size and shape. Fragmentation of the
glycan can have several factors, such as energy level applied
to ion and the charge state of the ion. There are two major
ions produced, the ion from the glycosidic cleavage between
sugar ring and the ion from cross-ring cleavages. Both major
ions can provide linkage information of glycan.
6. Cancer Glycoproteomics
Aberrant protein glycosylation may result due to genetic
defects, cancer, and inﬂammation. These changes in protein
glycosylation may result in abnormal changes in biological
function/activity, protein folding, and molecular recognition
in cancer. The site of protein glycosylation and the structure
of the oligosaccharide could be altered during initiation or
progression of disease. For example, oligosaccharides such
as polysialic acid, sialic acid α2,6-linked to galactose, β1-6
branching, and extended lactoseries chains (antigens) have
beenknowntobealteredincancer[78].Thereha v ebeengly-
coproteinbiomarkerstudieswithidentiﬁcationandproﬁling
of glycoprotein/glycan to help early diagnosis and develop-
ment of new therapeutics. Current advanced technologies
provideenhancedabilitytodetectglycoproteins/glycanswith
increased dynamic range and lower detection limit of ana-
lytes from complex protein lysates such as plasma [79, 80],
serum [81, 82], tissues [83, 84], and bodily ﬂuids [85, 86].
These advanced technologies also facilitate analyte quantiﬁ-
cation using labeling [87] or label-free [88] methods. There
are several studies for N-linked glycoproteins associated with
cancer including prostate cancer [89], ovarian cancer [90],
and breast cancer [91], as well as for O-linked glycoproteins
associated with disease, including prostate cancer [92]a n d
colon cancer [93]. Also, N- and O-linked glycans have been
studied for cancer biomarkers [94, 95]wi t hgl y c a nm a s sp r o -
ﬁling, since there is alteration in the branching and diﬀer-
ential expression of glycoforms [96]. Analysis of individual
glycans may be more suitable for biomarker studies, in spite
of diﬃculty of study due to complexity of target itself, by
using speciﬁc isoform and linkage information in the future.
7. Glycoproteomic Analysisof ProstateCancer
Prostate cancer is the most common cancer in men in the
United States, with an estimated 186,320 newly diagnosed
cases and 28,660 deaths in 2008 [97]. Currently, the serum
glycoprotein PSA is used clinically for mass population
screeningforprostatecancer.Unfortunately,however,assess-
ment of PSA levels does not have the required speciﬁcity for
a deﬁnitive prostate cancer diagnosis. This is due, in part, to
the observed increase in expression of this protein in other
prostatic pathologies such as benign prostatic hyperplasia
(BPH) or prostatitis (prostate gland infection or inﬂam-
mation). PSA also increases with age and infections of the
prostate. Oligosaccharide proﬁling by mass spectrometry
showed that PSA from prostate cancer sera has a higher con-
tent of α2,3-linked sialic acid than that from seminal ﬂuid
[98]. Lectin aﬃnity column chromatography followed by
the determination of total and free PSA by immunoassay
has shown lower α2,6-linked sialic acid in serum free PSA
from prostate cancer than that from BPH and higher α2,3-
linked sialic acid in serum free PSA from cancer compared
to BPH [99]. More recently, Meany and colleagues [100]
demonstrated in a pooled sera study that α2,3-linked and
α2,6-linked sialylation of PSA are more heterogeneous in
cancer than in noncancer. Li and colleagues [101] monitored
glycosylated and sialylated prostate-speciﬁc antigen (PSA) in
prostate cancer and noncancerous tissues. They coupled a
glycopeptide extraction strategy for speciﬁc glycosylation
with selected reaction monitoring (SRM). Results of this
study demonstrated that the relative abundance of glyco-
sylated PSA isoforms were not correlated with total PSA
protein levels measured in the same prostate cancer tissue
samplesbyclinicalimmunoassay.Furthermore,thesialylated
PSA was diﬀerentially distributed in cancer and noncancer
tissues. These data suggest that diﬀerently glycosylated iso-
forms of glycoproteins can be quantitatively analyzed and
may provide useful information for clinically relevant stud-
ies.
8. Glycoproteomics of OvarianCancer
Ovarian carcinoma is the leading cause of death from gyne-
cological cancers in many Western countries. Machado et al.
[90] analyzed N-linked glycans in the SKOV3 ovarian can-
cercelllineandonrecombinant-secretedglycoproteineryth-
ropoietin (EPO) expressed by transfected SKOV3 cells. The
N-glycans were released using PNGase F and were then de-
salted and analyzed by high-performance anion exchange
chromatography with pulsed amperometric detection and
MALDI-TOF/TOF mass spectrometry. High-mannose type
and fucosylated, complex type of glycans were found in the
SKOV3 cancer cell line; predominant core-fucosylated struc-
ture glycans and partial LacdiNAc motif glycans were found
on secreted recombinant human EPO. A large amount of
N-acetylneuraminic acid in α-2,3-linkage was detected as
were endogenous glycoproteins containing the LacdiNAc
motifinN-linkedglycans.Thestudysuggeststhathigh-man-
nose type glycans and LacdiNAc motif glycans may have a
role as potential biomarkers for ovarian cancer. Abbott and
colleagues [102] performed comparative glycotranscriptome
analysis of ovarian cancer and normal ovarian tissues. Multi-
ple lectins were utilized followed by nano-LC-linear ion trap6 International Journal of Proteomics
mass spectrometry. The identiﬁed proteins were veriﬁed by
immunoprecipitation and lectin blot detection. The study
showed 47 potential tumor-speciﬁc lectin reactive biomark-
ers for ovarian cancer; periostin and thrombospondin were
presented as tumor-speciﬁc glycan changes that can be used
to distinguish ovarian cancer patient serum from normal
serum.
N- and O-linked glycans have also been analyzed as po-
tential ovarian cancer biomarkers [94, 95]b yg l y c a nm a s s
proﬁling, since there is alteration in the branching and
diﬀerential expression [103]. Bereman and colleagues [48]
reported plasma glycan proﬁling in 10 ovarian tumors, 10
controls with a diﬀerential diagnosis of benign gynecologic
tumors,and10healthycontrolsusingnano-HPLC-MSusing
reverse phase and amide-based stationary phase column
under hydrophilic interaction. The experimental data sug-
gests that amide-based stationary phase columns may have
more robustness with high mass-measurement accuracy. Re-
sults of a comparison of glycan proﬁling between tumor, be-
nign tumor and normal, two fucosylated glycans showed
overexpressioninhealthycontrols.Analysisofindividualgly-
cans may be more suitable for biomarker studies, using spe-
cific isoform and linkage information in the future.
9. Glycoproteomics of Breast Cancer
There is growing evidence that glycan structures on glyco-
proteins are modiﬁed in breast cancer [104–113]. Breast-
cancer-associated alterations have been demonstrated for
fucosylation groups and for sialylations on the plasma pro-
tein α-1-proteinase inhibitor [110]. Increased GlcNAc β1-
6Man α1-6Man β-branching in asparagine-linked oligosac-
charides has been observed in human tumor cells. The levels
of the β1-6 branched oligosaccharides were evaluated in
a series of benign and malignant human breast biopsies.
Normal human breast tissue and benign lesions showed low
expression, but 50% of the primary malignancies exam-
ined showed signiﬁcantly elevated β1-6 branching [111].
Subsequently, L-PHA (a lectin that binds speciﬁcally to the
β1-6 branched oligosaccharides) lectin histochemistry was
performed on paraﬃn sections of human breast tissues.
All breast carcinomas and epithelial hyperplasia with atypia
demonstrated signiﬁcantly increased L-PHA staining as
compared to ﬁbroadenomas and hyperplasia without atypia
[112]. More recently, L-PHA reactive glycoproteins were
identiﬁed from matched normal (nondiseased) and malig-
nant tissue isolated from patients with invasive ductal breast
carcinoma [113]. Comparison analysis of the data identiﬁed
34 proteins that were enriched by L-PHA fractionation in
tumor relative to normal tissue for at least 2 cases of ductal
invasive breast carcinoma. Of these 34 L-PHA tumor en-
r i c h e dp r o t e i n s ,1 2w e r ec o m m o nt oa l l4m a t c h e dc a s e s
analyzed.
Rudd and coworkers [114] analyzed ﬂuorescently tagged
serum N-glycans of advanced breast cancer patients using
exoglycosidases and LC-MS/MS. They found that the expres-
sion of a trisialylated triantennary glycan containing an α-
1,3-linked fucose was increased in the presence of breast
cancer. Novotny and coworkers proﬁled the permethylated
N-glycans in sera of breast cancer patients at diﬀerent
stages (stages I to IV) using MALDI TOF/TOF MS in one
study [115]. In a second study, they proﬁled reduced and
methylated serum N-glycans of late-stage breast cancer
patients using nanoliquid chromatography (LC) Chip/time-
of-ﬂight (TOF) MS [116]. In both studies, they found an
increase in fucosylation in both core and branched segments
of N-glycans in the presence of breast cancer. In the latter
study, they found a decrease in expression of a biantennary-
monosialylated N-linked glycan and an increase in expres-
sion of a fucosylated triantennary-trisialylated N-linked gly-
can in the presence of stage IV breast cancer. These gly-
cosylation changes in a tumor-secreted protein may reﬂect
fundamental activity changes in the enzymes involved in the
glycosylation pathway, either through altered levels of en-
zymesoralteredenzymaticactivity.Importantly,thechanges
inglycanstructuremayserveasearlydetectionbiomarkersof
breast cancer.
10. Summary
Glycoproteomic analysis has become an important part of
proteomics because not only does glycosylation reveal bi-
ological changes in terms of disease, but also it is possible
to study glycoprotein/glycan in depth with the recent devel-
opment of new mass spectrometry technology. For isolation
and detection of glycoprotein/glycopeptides and glycans, an
enrichment process using aﬃnity chromatography followed
by mass spectrometry with MS/MS can be used with quanti-
tation. There is still massive, intense, manual data processing
for studying glycan structure analysis, however, bioinformat-
ics with various algorithms and glycol-related database has
been developed to help analyze glycoprotein and glycan. The
study of glycoproteomics is technically challenging yet has
begun to produce promising results to identify biomarkers
for early diagnosis and disease therapeutics.
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